Kosuke Doki

Kosuke Doki

Centre For Applied Pharmacokinetic Research, Division Of Pharmacy & Optometry, University Of Manchester, Manchester, Uk Department Of Pharmaceutical Sciences, Faculty Of ...

Direct Impact

Concepts for which Kosuke Doki has direct influence:

cyp2d6 genotype
serum flecainide
scn5a promoter haplotype
supraventricular tachyarrhythmia
mail transport
therapeutic range
interior temperature

External impact

Concepts related to the work of other authors for which Kosuke Doki has influence:

skin rash
uraemic toxins
antiarrhythmic drugs
serum flecainide
genetic polymorphisms
therapeutic drug monitoring
estimated glomerular filtration rate

Prominent publications by Kosuke Doki

KOL-Index: 35 Renal dysfunction results in the accumulation of various uremic toxins, including indoxyl sulphate (IS), and is a major risk factor for atrial fibrillation (AF). Experimental studies have demonstrated that IS exacerbates atrial remodelling via oxidative stress, inflammation, and fibrosis. However, its clinical impact on AF-promoting cardiac remodelling has not been described. Therefore, the ...
Known for
Recurrence Identified | Ablation Serum | Sulphate Atrial
KOL-Index: 31 OBJECTIVE: To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. METHODS: Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated with oral flecainide for supraventricular ...
Known for
Ims Pms | N79 | Determinant Factor | Intermediate Metabolizers
KOL-Index: 29 Flecainide, an anti-arrhythmic drug, undergoes renal excretion through active renal tubular secretion in addition to passive glomerular filtration. The contribution of renal uptake and efflux transporters in active renal tubular secretion of flecainide remains unclear except that flecainide is a substrate of human multidrug resistance protein 1 (MDR1). To elucidate renal efflux and uptake ...
Known for
Passive Glomerular Filtration | Hoct2-Chinese Hamster | Renal Tubular Secretion | Vivo Drug-Drug Interaction
KOL-Index: 27 Older patients are generally not included in Phase 1 clinical trials despite being the population group who use the largest number of prescription medicines. Physiologically based pharmacokinetic (PBPK) modelling provides an understanding of the absorption and disposition of drugs in older patients. In this review, PBPK models used for the prediction of absorption and exposure of drugs after ...
Known for
Predicted Drug Pharmacokinetics | Phase 1 Trials | Largest Number | Modelling Bioequivalence
KOL-Index: 25 BACKGROUND: Therapeutic drug monitoring (TDM) and dose adjustment of lenvatinib may be beneficial in the treatment of radioiodine-refractory thyroid cancer, by maximizing antitumor effects and minimizing adverse drug reactions. The aim of this study was, therefore, to develop and validate a high-performance liquid chromatography method using an ultraviolet detection system for routine serum ...
Known for
Extraction Octadecylsilyl | Lenvatinib Coefficients
KOL-Index: 24 Majority of bioequivalence studies are conducted in healthy volunteers. It has been argued that bioequivalence may not necessarily hold true in relevant patient populations due to a variety of reasons which affect one formulation more than the other for instance in achlorhydric patients where elevated gastric pH may lead to differential effects on formulations which are pH-sensitive with ...
Known for
Nifedipine Formulations | Achlorhydric Pbpk | Bio Relevant | Auc Ratios
KOL-Index: 23 The reported therapeutic range for trough flecainide concentration is 200-1000 ng mL(-1). Severe adverse events, such as ventricular arrhythmias, have occurred occasionally in patients whose serum flecainide exceeded 1000 ng mL(-1). However, the lower limit remains controversial. We have evaluated blood flecainide concentrations in patients with tachyarrhythmia who received the drug to ...
Known for
Trough Flecainide | Paroxysm | Concentrations 300 | Qrs Values
KOL-Index: 22 BACKGROUND: Erlotinib is used for treating non-small cell lung cancer (NSCLC). Intestinal absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of gastric acid suppressants may provide lower blood concentration of erlotinib. We investigated the effects of erlotinib coadministration with proton pump inhibitors (PPIs) and histamine H2 receptor blockers ...
Known for
Groups Coadministration | Ppi H2rb | Concentration Erlotinib | Acid Suppressants
KOL-Index: 20 OBJECTIVES: The aim was to compare blood tacrolimus concentrations in anaemic patients between affinity column-mediated immunoassay (ACMIA) and microparticle enzyme immunoassay (MEIA). METHODS: Blood concentrations of tacrolimus in 235 whole-blood samples from 64 patients treated with tacrolimus were determined by the two assay methods. Fifty-three samples had low haematocrit (Ht) values ...
Known for
Routine Monitoring | Corrected Concentrations | Tacrolimus Concentration | Calculated Meia

Centre for Applied Pharmacokinetic Research, Division of Pharmacy & Optometry, University of Manchester, Manchester, UK Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan

https://www.g2.com/products/key-opinion-leaders-kols/reviews https://www.bbb.org/us/fl/doral/profile/data-analytics/key-opinion-leaders-0633-92023858 https://www.trustpilot.com/review/keyopinionleaders.com https://www.yelp.com/biz/key-opinion-leaders-miami


© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172